Cite
Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC).
MLA
Vlachou, Evangelia, et al. “Outcomes of Enfortumab Vedotin (EV) Therapy in Relation to Prior Immune Checkpoint Inhibitor (ICI) in Patients (Pts) with Advanced Urothelial Cancer (AUC).” Journal of Clinical Oncology, vol. 42, Feb. 2024, p. 570. EBSCOhost, https://doi.org/10.1200/JCO.2024.42.4_suppl.570.
APA
Vlachou, E., Elias, R., Hahn, N. M., McConkey, D. J., Johnson, B. A., & Hoffman-Censits, J. H. (2024). Outcomes of enfortumab vedotin (EV) therapy in relation to prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial cancer (aUC). Journal of Clinical Oncology, 42, 570. https://doi.org/10.1200/JCO.2024.42.4_suppl.570
Chicago
Vlachou, Evangelia, Roy Elias, Noah M. Hahn, David James McConkey, Burles Avner Johnson, and Jean H. Hoffman-Censits. 2024. “Outcomes of Enfortumab Vedotin (EV) Therapy in Relation to Prior Immune Checkpoint Inhibitor (ICI) in Patients (Pts) with Advanced Urothelial Cancer (AUC).” Journal of Clinical Oncology 42 (February): 570. doi:10.1200/JCO.2024.42.4_suppl.570.